The UPTAKE study: Implications for the future of COVID-19 vaccination trial recruitment in UK and beyond

Abstract

Background: Developing a safe and effective vaccine will be the principal way of controlling the COVID-19 pandemic. However, current COVID-19 vaccination trials are not adequately representing a diverse participant population in terms of age, ethnicity and comorbidities. Achieving the representative recruitment targets that are adequately powered to the study remains one of the greatest challenges in clinical trial management. To ensure accuracy and generalizability of the safety and efficacy conclusions generated by clinical trials, it is crucial to recruit patient cohorts as representative as possible of the future target population. Missing these targets can lead to reduced validity of the study results, and can often slow down drug development leading to costly delays. This study explores the key factors related to perceptions and participation in vaccination trials. Methods: This study involved an anonymous cross-sectional online survey circulated across the UK. Statistical analysis was done in six phases. Multi-nominal logistic models examined demographic and geographic factors that may impact vaccine uptake. Results: The survey had 4884 participants of which 9·44% were BAME (Black Asian Minority Ethnic). Overall 2020 (41.4%) respondents were interested in participating in vaccine trials; 27.6% of the respondents were not interested and 31.1.% were unsure. The most interested groups were male (OR=1.290), graduates (OR=1.277), the 40-49 and 50-59 age group (OR=1.880 and OR=1.460 respectively) and those with no health issues (OR=1.064). The least interested groups were BAME (OR=0.427), those from villages and small towns (OR=0.66 and 0.54 respectively), and those aged 70 and above (OR=1.11).Conclusions: In order to have a vaccination that is generalizable to the entire population, greater work needs to be done in engaging a diverse cohort of participants. Public health campaigns need to be targeted in improving trial recruitment rates for the elderly, BAME community and the less educated rural population.